This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (previously presented): A method of treatment of a patient undergoing opioid analgesic therapy which comprises minimizing or mitigating the side effects of the opioid by the administration of a therapeutically effective amount of devazepide.

Claim 2. (previously presented): A method of treatment of a patient requiring analgesia which comprises the administration of a therapeutically effective amount of an opioid analgesic whilst minimising the side effects of the opioid by the separate, simultaneous or sequential administration of a therapeutically effective amount of devazepide.

Claim 3. (currently amended): A method according to claim 1 characterised characterized in that the ~~opioid~~ analgesic is selected from the group consisting of morphine, ~~or a salt thereof such as the sulphate, chloride or hydrochloride~~, meperidine, pentazocine, dextromoramide, diphenoxylate, dipipanone, meptazinol, methadone, nalbuphine, phenadoxone, phenazocine, remifentanil, tramadol, ~~or the other~~ a 1,4-hydroxymorphinan opioid analgesics ~~such as naloxone, meperidine, butorphanol, or pentazocine, or morphine-6-glucuronide, codeine, dihydrocodeine, diamorphinem dextropropoxyphene, pethidine, fentanyl, alfentanil, alphaprodine, buprenorphine, dextromoramide, diphenoxylate, dipipanone, heroin (diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, meptazinol, methadone, metopon (methyldihydromorphinone), nalbuphine, oxycodone, (dihydrohydroxycodeinone), oxymorphone (dihydrohydroxymorphinone), phenadoxone, phenazocine, remifentanil, tramadol, or~~ a salt of any of ~~these~~ the aforementioned, and combinations thereof.

Claim 4. (currently amended): A method according to claim 1 ~~characterised~~ characterized in that the ~~opioid~~ analgesic is selected from the group consisting of morphine, ~~or a salt thereof such as~~

~~the sulphate, chloride or hydrochloride~~, meperidine, pentazocine, dextromoramide, diphenoxylate, dipipanone, meptazinol, methadone, nalbuphine phenadoxone phenazocine, remifentanil, tramadol, or the other a 1,4-hydroxymorphinan opioid analgesics such as naloxone, meperidine, butorphanol, or pentazocine, or morphine-6-glucuronide, codeine, dihydrocodeine, diamorphine, dextropropoxyphene, pethidine, fentanyl, alfentanil, alphaprodine, buprenorphine, dextromoramide, diphenoxylate, dipipanone, heroin (diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, meptazinol, methadone, metopon (methyldihydromorphinone), nalbuphine, oxymorphone (dihydrohydroxymorphinone), tramadol, or a salt of any of these the aforementioned, and combinations thereof.

Claim 5. (previously presented): A method according to claim 3 characterised in that the opioid is selected from the group hydromorphone, oxycodone, morphine and fentanyl.

Claim 6. (previously presented): A method according to claim 4 characterised in that the opioid is selected from the group hydromorphone, oxycodone, morphine and fentanyl.

Claim 7. (previously presented): A method according to claim 5 characterised in that the opioid is selected from the group morphine and morphine sulphate.

Claim 8. (previously presented): A method according to claim 6 characterised in that the opioid is selected from the group morphine and morphine sulphate.

Claim 9. (previously presented): A method according to claim 1 characterised in that the method of delivery of the devazepide and/or the opioid is selected from the group, administration intravenously, orally, intrathecally, intranasally, intrarectally, intramuscularly/subcutaneously, by inhalation and by transdermal patch.

Claim 10. (previously presented): A method according to claim 2 characterised in that the method of delivery of the devazepide and/or the opioid is selected from the group, administration

intravenously, orally, intrathecally, intranasally, intrarectally, intramuscularly/subcutaneously, by inhalation and by transdermal patch.

Claim 11. (previously presented): A method according to claim 9 characterised in that the devazepide is administered intravenously or orally.

Claim 12. (previously presented): A method according to claim 10 characterised in that the devazepide is administered intravenously or orally.

Claim 13. (previously presented): A method according to claim 11 characterised in that the devazepide is administered orally.

Claim 14. (previously presented): A method according to claim 12 characterised in that the devazepide is administered orally.

Claim 15. (previously presented): A method according to claim 9 characterised in that the opioid is administered intravenously and the devazepide is administered intravenously.

Claim 16. (previously presented): A method according to claim 10 characterised in that the opioid is administered intravenously and the devazepide is administered intravenously.

Claim 17. (previously presented): A method according to claim 9 characterised in that the opioid is administered orally and the devazepide is administered orally.

Claim 18. (previously presented): A method according to claim 10 characterised in that the opioid is administered orally and the devazepide is administered orally.

Claim 19. (previously presented): A method according to claim 9 characterised in that the opioid is administered by intravenous administration or oral administration.

Claim 20. (previously presented): A method according to claim 10 characterised in that the opioid is administered by intravenous administration or oral administration.

Claim 21. (previously presented): A method according to claim 1 characterised in that the daily dosage of devazepide is up to 0.7 mg/kg/day.

Claim 22. (previously presented): A method according to claim 2 characterised in that the daily dosage of devazepide is up to 0.7 mg/kg/day.

Claim 23. (previously presented): A method according to claims 21 characterised in that the daily dosage of devazepide is from 25 ug/kg/day to 0.7 mg/kg/day.

Claim 24. (previously presented): A method according to claims 22 characterised in that the daily dosage of devazepide is from 25 ug/kg/day to 0.7 mg/kg/day.

Claim 25. (previously presented): A method according to claim 23 characterised in that the daily dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 26. (previously presented): A method according to claim 24 characterised in that the daily dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 27. (previously presented): A method according to claim 25 characterised in that the devazepide is administered orally and the daily dosage of devazepide is from 0.07 mg/kg/day to 0.29 mg/kg/day.

Claim 28. (previously presented): A method according to claim 26 characterised in that the devazepide is administered orally and the daily dosage of devazepide is form 0.07 mg/kg/day to 0.29 mg/kg/day.

Claim 29. (previously presented): A method according to either of claims 25 characterised in that the devazepide is administered intravenously administration the dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 30. (previously presented): A method according to either of claims 26 characterised in that the devazepide is administered intravenously administration the dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 31. (previously presented): A method according to claim 1 characterised in that the daily dosage of the opioid is from 5 to 2000 mg daily.

Claim 32. (previously presented): A method according to claim 2 characterised in that the daily dosage of the opioid is from 5 to 2000mg daily.

Claim 33. (previously presented): A method according to claim 31 characterised in that the daily dosage of the opioid is from 5 to 100mg daily.

Claim 34. (previously presented): A method according to claim 32 characterised in that the daily dosage of the opioid is from 5 to 100mg daily.

Claim 35. (previously presented): A method according to claim 1 characterised in that the side effect which is inhibited, mitigated or minimised is selected from the group, constipation, dizziness, tiredness/fatigue and vomiting.

Claim 36. (previously presented): A method according to claim 2 characterised in that the side effect which is inhibited, mitigated or minimised is selected from the group, constipation, dizziness, tiredness/fatigue and vomiting.

Claim 37. (previously presented): A method according to claim 1 characterised in that the devazepide used is the S enantiomer wherein the level of R enantiomer is not greater than 1.5% w/w.

Claim 38. (previously presented): A method according to claim 2 characterised in that the devazepide used is the S enantiomer wherein the level of R enantiomer is not greater than 1.5% w/w.

Claim 39. (previously presented): The use of devazepide in the manufacture of a medicament which inhibits or mitigates the undesirable side effects of administration of a therapeutically effective amount of an opioid analgesic.

Claim 40. (previously presented): The use according to claim 39 characterised in that the devazepide used is the S enantiomer wherein the level of R enantiomer is not greater than 1.5% w/w.

Claim 41. (currently amended): The use of devazepide in the manufacture of a medicament for use in the method of either of claim 1.

Claim 42. (currently amended): The use of devazepide in the manufacture of a medicament for use in the method of either of claim 2.

Claim 43. (new): A method according to claim 3 wherein the morphine is a morphine salt selected from the group consisting of sulphate, chloride, and hydrochloride.

Claim 44. (new): A method according to claim 3 wherein the 1,4 hydroxymorphinan opioid analgesic is selected from the group consisting of butorphanol, morphine-6-glucuronide, codeine, dihydrocodeine, diamorphine, buprenorphine, heroin (diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, metopon (methyldihydromorphinone), oxycodone (dihydrohydroxycodeinone), oxymorphone (dihydrohydroxymorphinone), a salt of any of the aforementioned, and combinations thereof.

Claim 45. (new): A method according to claim 4 wherein the morphine is a morphine salt selected from the group consisting of sulphate, chloride, and hydrochloride.

Claim 46. (new): A method according to claim 4 wherein the 1,4 hydroxymorphinan opioid analgesic is selected from the group consisting of butorphanol, morphine-6-glucuronide, codeine, dihydrocodeine, diamorphine, buprenorphine, heroin (diacetylmorphine), hydrocodone

(dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, metopon (methyldihydromorphinone), oxycodone (dihydrohydroxycodeinone), oxymorphone (dihydrohydroxymorphinone), a salt of any of the aforementioned, and combinations thereof.